September 11th 2025
Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.
September 10th 2025
William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.
September 3rd 2025
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.
September 2nd 2025
Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
COVID-19's Impact on Alzheimer's: Uncovering 2 Years of Mortality Trends
July 17th 2023This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.
Read More
COVID-19 Vaccines Bridge Socioeconomic Disparities in Pandemic Impact, CDC Study Shows
July 13th 2023This study analyzed 81 communities in Los Angeles and found that once vaccines became widely available, there was no significant difference in COVID-19 incidence between communities of varying income levels.
Read More
Can Immunomodulators Reduce Recovery Time in Patients Hospitalized With COVID-19 Pneumonia?
July 11th 2023Researchers investigated abatacept, cenicriviroc, and infliximab, but found that these medications did not significantly impact the time to recovery from COVID-19 pneumonia compared to placebo.
Read More
Novavax as a Second Dose: A Potential Game Changer for Adolescent COVID-19 Vaccination
July 6th 2023The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.
Read More
Using Comorbidities and Demographics to Predict COVID-19 Outcomes in the Midwest
June 27th 2023In Indiana, COVID-19 patients with chronic obstructive pulmonary disease, cardiovascular disease, and type 2 diabetes had significantly higher mortality rates than COVID-19 patients without these comorbidities.
Read More
Unraveling the Connection: How Air Pollution Aggravates COVID-19 and Prolongs Hospital Stays
June 23rd 2023Even low levels of air pollution make COVID-19 worse, this study found. Air pollution exposure was associated with more severe disease, longer hospitalization periods, and an increased likelihood of intensive care admission.
Read More
Innovative ABNCoV2 COVID-19 Booster Vaccine Induces Long-Lasting Protection
June 20th 2023ABNCoV2, a non-adjuvanted COVID-19 booster vaccine by Bavarian Nordic, demonstrates promising results in phase 2 trials. The vaccine generates strong immune responses, neutralizing multiple variants of concern, including Beta, Delta, and Omicron.
Read More
Online Harassment of Physicians and Scientists During the COVID-19 Pandemic
June 20th 2023This past weekend, vaccine scientist and physician Peter Hotez, MD, PhD, was stalked outside his home after facing online scrutiny from Twitter CEO Elon Musk and controversial podcaster Joe Rogan. His story is severe, but Hotez is far from the first health advocate to be harassed online since the COVID-19 pandemic.
Read More
COVID-19 Rebound Found More in Hospitalized Patients With Existing Health Problems
June 9th 2023A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.
Read More
COVID-19 Public Health Emergency Is Over. What Have We Learned?
June 7th 2023As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.
Read More
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831